Adial Pharmaceuticals, Inc. received a letter on September 2, 2025, granting them an additional 180 days to meet the $1.00 minimum bid price requirement for Nasdaq listing compliance, until March 2, 2026. The company may consider a reverse stock split if necessary to regain compliance.